Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced positive results of an ex-U.S. proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED).
Novartis today announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).
Vifor Pharma announced that its hypertension and chronic kidney disease (CKD) drug Veltassa (patiromer) has met its primary endpoint in phase II Amber study.
Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) plus radiation has failed to meet its primary endpoint of overall survival (OS) in phase 3 brain cancer trial.
Merck, known as MSD outside of the US and Canada, announced results from a Phase 2 trial (NCT02982972 ) evaluating the safety, tolerability and immunogenicity of V114.
Merck announced the presentation of results of a phase 3 trial evaluating the efficacy and safety of BELSOMRA (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer’s disease dementia.
Xencor has dosed the first patient in a phase 1 clinical trial that will evaluate its bispecific antibody XmAb23104 for the treatment of advanced solid tumors.
AstraZeneca announced that its blood cancer drug Calquence (acalabrutinib) has met its primary endpoint at interim analysis in the phase III Ascend (ACE-CL-309) trial.
PharmaCyte Biotech, a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced that advances have been completed in the manufacturing process for the clinical trial product that will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
Pear Therapeutics, Inc. announced the start of a feasibility study for a prescription digital therapeutic (PDT) intended to treat depressive symptoms in people with Multiple Sclerosis (MS). Known as Pear-006, the PDT is intended to be used in combination with disease-modifying treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.